OBJECTIVE: Limited data are available about risk factors for the progression of aortic stiffness in healthy population. We examined several risk factors as possible independent predictors of aortic stiffness progression among a population-based sample of US men. METHODS: A total of 240 men (40-49 years) free of CVD at baseline from the Pittsburgh site of the ERA JUMP study were evaluated. Aortic stiffness was measured as carotid-femoral pulse wave velocity at baseline and after 4.6 ± 0.2 (mean ± SD) years of follow-up. Progression of aortic stiffness was evaluated as relative annual change in carotid-femoral pulse wave velocity (% change/year). Using linear regression, both baseline potential risk factors and their annual changes were evaluated as possible risk factors for aortic stiffness progression. Baseline age, follow-up time, race, heart rate, and medications use were forced in all models. RESULTS: During follow-up, relative to baseline level, aortic stiffness increased 0.3% ± 5.3% per year. In final models, the independent predictors of degree of aortic stiffness progression were lower levels of adiponectin (P = 0.03), higher levels of systolic blood pressure (P = 0.03), greater annual change in systolic blood pressure (P = 0.04), and alcohol consumption ≥ 2 times/week (P = 0.02). Adiponectin levels within the third (9.8 μg/Ml ≤ adiponectin < 13.0 μg/mL) and the fourth (adiponectin ≥ 13.0 μg/mL) quartiles were associated with an improvement in relative annual aortic stiffness progression (P = 0.02, P = 0.01, respectively) compared to levels within the first quartile (adiponectin ≤ 7.0 μg/mL). CONCLUSION: Among apparently healthy men, lower levels of baseline adiponectin could be a novel marker for greater risk of aortic stiffness progression. Longitudinal research is required to evaluate whether adiponectin change over time would have similar association with aortic stiffness progression.
OBJECTIVE: Limited data are available about risk factors for the progression of aortic stiffness in healthy population. We examined several risk factors as possible independent predictors of aortic stiffness progression among a population-based sample of US men. METHODS: A total of 240 men (40-49 years) free of CVD at baseline from the Pittsburgh site of the ERA JUMP study were evaluated. Aortic stiffness was measured as carotid-femoral pulse wave velocity at baseline and after 4.6 ± 0.2 (mean ± SD) years of follow-up. Progression of aortic stiffness was evaluated as relative annual change in carotid-femoral pulse wave velocity (% change/year). Using linear regression, both baseline potential risk factors and their annual changes were evaluated as possible risk factors for aortic stiffness progression. Baseline age, follow-up time, race, heart rate, and medications use were forced in all models. RESULTS: During follow-up, relative to baseline level, aortic stiffness increased 0.3% ± 5.3% per year. In final models, the independent predictors of degree of aortic stiffness progression were lower levels of adiponectin (P = 0.03), higher levels of systolic blood pressure (P = 0.03), greater annual change in systolic blood pressure (P = 0.04), and alcohol consumption ≥ 2 times/week (P = 0.02). Adiponectin levels within the third (9.8 μg/Ml ≤ adiponectin < 13.0 μg/mL) and the fourth (adiponectin ≥ 13.0 μg/mL) quartiles were associated with an improvement in relative annual aortic stiffness progression (P = 0.02, P = 0.01, respectively) compared to levels within the first quartile (adiponectin ≤ 7.0 μg/mL). CONCLUSION: Among apparently healthy men, lower levels of baseline adiponectin could be a novel marker for greater risk of aortic stiffness progression. Longitudinal research is required to evaluate whether adiponectin change over time would have similar association with aortic stiffness progression.
Authors: Mehret S Birru; Karen A Matthews; Rebecca C Thurston; Maria M Brooks; Said Ibrahim; Emma Barinas-Mitchell; Imke Janssen; Kim Sutton-Tyrrell Journal: Am J Hypertens Date: 2011-04-14 Impact factor: 2.689
Authors: K Sutton-Tyrrell; R H Mackey; R Holubkov; P V Vaitkevicius; H A Spurgeon; E G Lakatta Journal: Am J Hypertens Date: 2001-05 Impact factor: 2.689
Authors: W S Yang; W J Lee; T Funahashi; S Tanaka; Y Matsuzawa; C L Chao; C L Chen; T Y Tai; L M Chuang Journal: J Clin Endocrinol Metab Date: 2001-08 Impact factor: 5.958
Authors: Robert S Lindsay; Tohru Funahashi; Robert L Hanson; Yuji Matsuzawa; Sachiyo Tanaka; P Antonio Tataranni; William C Knowler; Jonathan Krakoff Journal: Lancet Date: 2002-07-06 Impact factor: 79.321
Authors: Justin P Zachariah; Jian Rong; Martin G Larson; Naomi M Hamburg; Emelia J Benjamin; Ramachandran S Vasan; Gary F Mitchell Journal: Hypertension Date: 2017-12-26 Impact factor: 10.190
Authors: S J Reinstadler; G Klug; H J Feistritzer; A Mayr; K Bader; J Mair; R Esterhammer; M Schocke; B Metzler Journal: Eur Heart J Acute Cardiovasc Care Date: 2013-12-04
Authors: Angelo Scuteri; Christopher H Morrell; Marco Orrù; James B Strait; Kirill V Tarasov; Liana Anna Pina Ferreli; Francesco Loi; Maria Grazia Pilia; Alessandro Delitala; Harold Spurgeon; Samer S Najjar; Majd AlGhatrif; Edward G Lakatta Journal: Hypertension Date: 2014-09-15 Impact factor: 10.190